Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
postmenopausal female patients;
stage IV or locally advanced breast cancer;
measurable disease;
letrozole failure (Part 2);
Eastern Cooperative Oncology Group (ECOG) performance status \<=2.
You may not be if
previous chemotherapy for metastatic breast cancer;
concurrent antibody or immunotherapy for advanced disease, within 4 weeks prior to receipt of study drug;
history of primary malignancy in 5 years prior to study, excluding adequately treated basal or squamous cell cancer of skin, or cancer in situ of cervix;
concurrent radiotherapy, or radiotherapy within 28 days prior to receipt of study drug.
Clareo Health | A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer
